Researchers Working On Universal mRNA-Influenza Vaccine Aiming For Baseline Immune Memory For Diverse Strains

  • Researchers are working on an experimental pan-influenza vaccine based on the famed mRNA technology to provide broad protection.
  • The two-dose vaccine employs the same messenger RNA (mRNA) technology used in the COVID-19 shots developed by Pfizer Inc PFEBioNTech SE BNTX, and Moderna Inc MRNA.
  • Initial animal studies show that the experimental vaccine provided broader protection against all 20 known influenza A and B virus subtypes.
  • Antibody levels induced by the vaccine remained unchanged for at least four months, according to a report published in the journal Science.
  • According to a published U.S. study, the results potentially open a pathway to a universal flu shot that might help prevent future pandemics.
  • It delivers tiny lipid particles containing mRNA instructions for cells to create replicas of so-called hemagglutinin proteins that appear on influenza virus surfaces, Reuters reported.
  • Moderna and Pfizer have mRNA flu vaccines in late-stage human trials, and GSK Plc GSK and CureVac NV CVAC are testing an mRNA flu vaccine in an early-stage safety trial in humans.
  • Image by Gerd Altmann from Pixabay
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!